Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction

Genes and Development

Volumn 9, Issue 7, 1995, Pages 794-807

  Bugge, Thomas H ^a,b   Flick, Matthew J ^a   Daugherty, Cynthia C ^a   Degen, Jay L ^a  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^b FINSEN LABORATORY   (Denmark)

Author keywords

fertility; gene targeting; Plasminogen; proenzyme activation; thrombosis

Indexed keywords

ESTERASE; FIBRIN; MESSENGER RNA; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEVELOPMENT; FERTILITY; FIBRIN DEPOSITION; FIBRINOLYSIS; GENE DISRUPTION; HEMOSTASIS; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; REPRODUCTION; SEXUAL MATURITY; THROMBOSIS; TRANSGENIC MOUSE; ULCER;

ANIMALIA; MUS MUSCULUS;

EID: 0028920904     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.9.7.794     Document Type: Article

References (65)

1. Aoki, N., M. Moroi, Y. Sakata, and N. Yoshida. 1978. Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis. J. Clin. Invest. 61: 1186-1195.
2. 572 to Pro mutation. Blood 82: 475-480.
3. Bell, S.M., R.W. Brackenbury, N.D. Leslie, and J.L. Degen. 1990. Plasminogen activator gene expression is induced by the src oncogene product and tumor promoters. J. Biol. Chem. 265: 1333-1338.
4. Bode, V.C. and M.A. Dziadek. 1979. Plasminogen activator secretion during mouse embryogenesis. Dev. Biol. 73: 272-289.
5. Carmeliet, P., L. Schoojans, L. Kieckens, B. Ream, J.L. Degen, R. Bronson, R. DeVos, J.J. van den Oord, D. Collen, and R.C. Mulligan. 1994. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368: 419-424.
6. Cesarman, G.M., C.A. Guevara, and K.A. Hajjar. 1994. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA): Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J. Biol. Chem. 269: 21198-21203.
7. Chomczynski, P. and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidimum thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156-159.
8. Collen, D. and H.R. Lijnen. 1994. Fibrinolysis and the control of hemostasis. In The molecular basis of blood diseases (ed. G.S. Stamatoyannopoulos, A.W. Nienhuis, P.W. Majerus, and H. Varmus), pp. 725-752. W.B. Saunders Co., Philadelphia, PA.
9. Crowley, C.W., R.L. Cohen, B.K. Lucas, G. Liu, M.A. Shuman, and A.D. Levinson. 1993. Prevention of metastasis by inhibition of the urokinase receptor. Proc. Natl. Acad. Sci. 90: 5021-5025.
10. Danø, K., P.A. Andreasen, J. Grøndahl-Hansen, P. Kristensen, L.S. Nielsen, and L. Skriver. 1985. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 44: 139-266.
11. Danø, K., N. Behrendt, N. Brünner, V. Ellis, M. Ploug, and C. Pyke. 1994. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 8: 189-203.
12. Degen, S.J.F., S.M. Bell, L.A. Schaefer, and R.W. Elliott. 1990. Characterization of the cDNA coding for mouse plasminogen and localization of the gene to mouse chromosome 17. Genomics 8: 49-61.
13. Deutsch, D.G. and E.T. Mertz. 1970. Plasminogen: Purification from human plasma by affinity chromatography. Science 170: 1095-1096.
14. Dolan, G., M. Greaves, P. Cooper, and F.E. Preston. 1988. Thrombovascular disease and familial plasminogen deficiency: A report of three kindreds. Br. J. Haematol. 70: 417-421.
15. Ellis, V. and K. Danø. 1992. The urokinase receptor and the regulation of cell surface plasminogen activation. Fibrinolysis 6: 27-34.
16. Friedman, G.C. and N. Seeds. 1994. Tissue plasminogen activator expression in the embryonic nervous system. Dev. Brain Res. 81: 41-49.
17. Girolami, A., F. Marafioti, M. Rubertelli, and M.G. Cappellato. 1986. Congenital heterozygous plasminogen deficiency associated with a severe thrombotic tendency. Acta Haematol. 75: 54-57.
18. Goldsmith, G.H., H. Saito, and O.D. Ratnoff. 1978. The activation of plasminogen by Hageman Factor (Factor XII) and Hageman Factor fragments. J. Clin. Invest. 62: 54-60.
19. Grainger, D.J., P.R. Kemp, A.C. Liu, R.M. Lawn, and J.C. Medcalfe. 1994. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature 370: 460-462.
20. Guy, C.T., R.D. Cardiff, and W.J. Muller. 1992. Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic model for metastatic disease. Mol. Cell. Biol. 12:954-961.
21. Heckel, J.L., E.P. Sandgren, J.L. Degen, R.D. Palmiter, and R.L. Brinster. 1990. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell 62: 447-456.
22. Hooper, M.L., K. Hardy, A. Handyside, S. Hunter, and M. Monk. 1987. HPRT-deficient (Lesch-Nyhan) mouse embryos derived from germline colonization by cultured cells. Nature 326: 292-295.
23. Ichinose, A., K. Fujikawa, and T. Suyama. 1986. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J. Biol. Chem. 261: 3486-3489.
24. Ichinose, A., E.S. Espling, J. Takamatsu, H. Saito, K. Shinmyozu, I. Maruyama, T.E. Petersen, and E.W. Davie. 1991. Two types of abnormal genes for plasminogen in families with a predisposition to thrombosis. Proc. Natl. Acad. Sci. 88: 115-119.
25. Kielberg, V., P.A. Andreasen, J. Grøndahl-Hansen, L.S. Nielsen, L. Skriver, and K. Danø. 1985. Proenzyme to urokinase-type plasminogen activator in the mouse in vivo. FEBS Lett. 182: 441-445.
26. Kikuchi, S., Y. Yamanouchi, L. Li, K. Kobayashi, H. Ijima, R. Miyazaki, S. Tsuchiya, and H. Hamaguchi 1992. Plasminogen with the type-I mutation is polymorphic in the Japanese population. Hum. Genet. 90: 7-11.
27. Kluft, C., G. Dooijeward, and J.J. Emeis. 1987. Role of the contact activation system in fibrinolysis. Semin. Thromb. Hemostasis 13: 50-68.
28. Kobayashi, H., M. Schmitt, L. Goretzki, N. Chucholowski, J. Calvete, M. Kramer, W.A. Günzler, F. Jänicke, and H. Graeff. 1991. Cathepsin B efficiently activates the soluble and the tumor-cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA). J. Biol. Chem. 266: 5147-5152.
29. Kook, Y. H., J. Adamski, A. Zelent, and L. Ossowski. 1994. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J. 13: 3983-3991.
30. Larsson, L.-I., L. Skriver, L.S. Nielsen, J. Gröndahl-Hansen, P. Kristensen, and K. Danø. 1984. Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse. J. Cell Biol. 98: 894-903.
31. Li, H., D.P. Witte, W.W. Branford, B.J. Aronow, M. Weinstein, S. Kaur, S. Wert, G. Singh, C.M. Schreiner, J.A. Whitsett, W.J. Scott, and S.S. Potter. 1994. Gsh-4 encodes a LIM-type homeodomain, is in the developing nervous system and is required for early postnatal survival. EMBO J. 13: 2876-2885
32. Lohnes, D., P. Kastner, A. Dierich, M. Mark, M. LeMeur, and P. Chambon. 1993. Function of retinoic acid receptor gamma in the mouse. Cell 73: 643-658.
33. Lottenberg, R., F.R. Dolly, and C.S. Kitchens. 1985. Recurrent thromboembolic disease and pulmonary hypertension associated with severe hypoplasminogenemia. Am. J. Hematol. 19: 181-193.
34. Mandle, R.J. and A.P. Kaplan. 1979. Hageman-Factor-dependent fibrinolysis: Generation of fibrinolytic activity by the interaction of human activated Factor XI and plasminogen, Blood 54: 850-862.
35. Mannucci, P.M., C. Kluft, D.W. Traas, P. Seveso, and A. D'Angelo. 1986. Congenital plasminogen deficiency associated with venous thromboembolism: Therapy trial with stanozolol. Br. J. Haematol. 63: 753-759.
36. Mansour, S.L., K.R. Thomas, and M.R. Capecchi. 1988. Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: A general strategy for targeting mutations to non-selectable genes. Nature 336: 348-352.
37. Marotti, K.R., D. Belin, and S. Strickland. 1982. The production of distinct forms of plasminogen activator by mouse embryonic cells. Dev. Biol. 90: 154-159.
38. Mignatti, P., E. Robbins, and D.B. Rifkin. 1986. Tumor cell invasion through the human amniotic membrane. Requirement for a proteinase cascade. Cell 47: 487-498.
39. Morioka, S., G.S. Lazarus, J.L. Baird, and P.J. Jensen. 1987. Migrating keratinocytes express urokinase-type plasminogen activator. J. Invest. Dermatol. 88: 418-423.
40. Moscatelli, D. and D.B. Rifkin. 1988. Membrane and matrix localization of proteases: A common theme in tumor cell invasion and angiogenesis. Biochim. Biophys. Acta 948: 67-85.
41. Odekon, L.E., F. Blasi, and D.B. Rifkin. 1994. Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-β to TGF-β. J. Cell. Physiol. 158: 398-407.
42. Olbricht, C.J., M. Fink, and E. Gutjahr. 1991. Alterations in liposomal enzymes of the proximal tubule in gentamicin nephrotoxicity. Kidney Int. 39: 639-646.
43. O'Reilly, M.S., L. Holmgren, Y. Shing, C. Chen, R.A. Rosenthal, M. Moses, W.S. Lane, Y. Cao, E.H. Sage, and J. Folkman. 1994. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastasis by Lewis lung carcinoma. Cell 79: 315-328.
44. Ossowski, L. and E. Reich 1983. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35:611-619.
45. Ossowski, L. 1988. Plasminogen activator dependent pathways in dissemination of human tumors in the chick embryo. Cell 52: 321-328.
46. Ossowski, L., G. Clunie, M.-T. Masucci, and F. Blasi. 1991a. In vivo paracrine interactions between urokinase and its receptor: Effect on tumor cell migration. J. Cell Biol. 115: 1107-1112.
47. Ossowski, L., H. Russo-Payne, and E.L. Wilson. 1991b. Inhibition of urokinase-type plasminogen activator by antibodies: The effect on dissemination of a human tumor in the nude mouse. Cancer Res. 51: 274-281.
48. Patrassi, G.M., M.T. Sartori, S. Piermarocchi, M. Viero, G. Boeri, and A. Girolami. 1993. Unusual thrombotic-like retinopathy (Coats' disease) associated with congenital plasminogen deficiency type 1. J. Int. Med. 234: 619-623.
49. Pepper, M.S., J.-D. Vassalli, R. Montesano, and L. Orci. 1987. Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. J. Cell Biol. 105: 2535-2541.
50. Petersen, T.E., M.R. Martzen, A. Ichinose, and E.W. Davie. 1990. Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. J. Biol. Chem. 265: 6104-6111.
51. Plump, A.S., J.D. Smith, T. Hayek, K. Aalto-Setala, A. Walsh , J.G. Verstuyft, E.M. Rubin, and J.L. Breslow. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71: 343-353.
52. Robbins, K.C. (1992). Dysplasminogenemias. Prog. Cardiovasc. Dis. 34: 295-308.
53. Rømer, J., L.R. Lund, J. Eriksen, C. Pyke, P. Kristensen, and K. Danø. 1994. The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. J. Invest. Dermatol. 102: 519-522.
54. Rudnicki, M.A., P.N. Schnegelsberg, R.H. Stead, T. Braun, H.H. Arnold, and R. Jaenish. 1993. MyoD or Myf-5 is required for the formation of skeletal muscle. Cell 75: 1351-1359.
55. Saksela, O. and D.B. Rifkin. 1988. Cell-associated plasminogen activation: Regulation and physiological functions. Annu. Rev. Cell. Biol. 4: 93-126.
56. Sappino, A.-P., J. Huarte, D. Belin, and J.-D. Vassalli. 1989. Plasminogen activators in tissue remodeling and invasion: mRNA localization in mouse ovaries and implanting embryos. J. Cell Biol. 109: 2471-2479.
57. Sappino, A.-P., J. Huarte, J.-D. Vassalli, and D. Belin. 1991. Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney. J. Clin. Invest. 87: 962-970.
58. Smith, G.E. and M.D. Summers. 1980. The bidirectional transfer of DNA and RNA to nitrocellulose or diazobenzyloxymethyl-paper. Anal. Biochem. 109: 123-129.
59. Strickland, S. and E. Reich. 1976. Plasminogen activation in early embryogenesis: Enzyme production by trophoblast and parietal endoderm. Cell 9: 231-240.
60. Suh, T.T., C. Nerlov, K. Danø, and J.L. Degen. 1994. The murine urokinase-type plasminogen activator receptor gene. J. Biol. Chem. 269: 25992-25998.
61. Valinsky, J.E. and E. Reich. 1981. Plasminogen activator in the bursa of Fabricius: Correlations with morphogenetic remodeling and cell migrations. Cell 25: 471-476.
62. van der Lugt, N., E.R. Maandag, H. teRiele, P.W. Laird, and A. Berns. 1991. A pgk-hprt fusion as a selectable marker for targeting genes in mouse embryonic stem cells: Disruption of the T-cell receptor δ-chain encoding gene. Gene 105: 263-267.
63. Vassalli, J.-D., A.-P. Sappino, and D. Belin. 1991. The plasminogen activator/plasmin system. J. Clin. Invest. 88: 1067-1072.
64. Vassalli, J.-D., A. Wohlwend, and D. Belin. 1992. Urokinasecatalyzed plasminogen activation at the monocyte/macrophage cell surface: A localized and regulated proteolytic system. Curr. Top. Microbiol. Immunol. 181: 65-86.
65. Werb, Z., C. Mainardi, C.A. Vater, and E.D. Harris. 1977. Endogenous activation of latent collagenases by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N. Engl. J. Med. 296: 1017-1023.